Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.

by Euphemia Y Leung, Marjan Askarian-Amiri, Graeme J Finlay, Gordon W Rewcastle, Bruce C Baguley
Published 2015-01-01

Inhibitors of pan PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth

by Melanie eSweetlove, Melanie eSweetlove, Emma eWrightson, Sharada eKolekar, Gordon W. Rewcastle, Gordon W. Rewcastle, Bruce C. Baguley, Bruce C. Baguley, Peter R. Shepherd, Peter R. Shepherd, Stephen M. F. Jamieson, Stephen M. F. Jamieson
Published 2015-06-01

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

by Euphemia Y Leung, Ji Eun Kim, Marjan Askarian-Amiri, Gordon W Rewcastle, Graeme J Finlay, Bruce C Baguley
Published 2014-01-01

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

by Khanh B. Tran, Sharada Kolekar, Anower Jabed, Patrick Jaynes, Jen-Hsing Shih, Qian Wang, Jack U. Flanagan, Gordon W. Rewcastle, Bruce C. Baguley, Peter R. Shepherd
Published 2021-02-01

Orthogonal assays for the identification of inhibitors of the single-stranded nucleic acid binding protein YB-1

by AlexanderJ. Trevarton, Yan Zhou, Dehua Yang, Gordon W. Rewcastle, Jack U. Flanagan, Antony Braithwaite, Peter R. Shepherd, Cristin G. Print, Ming-Wei Wang, Annette Lasham
Published 2019-09-01